Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone46-8-587-254-00
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.44 billion
Profitability
Miscellaneous
Employees3,800
Next Earnings Date8/29/2019 (Estimated)
OptionableNot Optionable
ELEKTA AB/ADR (OTCMKTS:EKTAY) Frequently Asked Questions
What is ELEKTA AB/ADR's stock symbol?
ELEKTA AB/ADR trades on the OTCMKTS under the ticker symbol "EKTAY."
How often does ELEKTA AB/ADR pay dividends? What is the dividend yield for ELEKTA AB/ADR?
ELEKTA AB/ADR declared a Semi-Annual dividend on Wednesday, January 30th. Shareholders of record on Monday, March 4th will be paid a dividend of $0.052 per share on Friday, March 22nd. The ex-dividend date is Friday, March 1st. View ELEKTA AB/ADR's Dividend History.
How were ELEKTA AB/ADR's earnings last quarter?
ELEKTA AB/ADR (OTCMKTS:EKTAY) posted its earnings results on Wednesday, May, 29th. The company reported $0.15 earnings per share (EPS) for the quarter. The business had revenue of $432.69 million for the quarter. ELEKTA AB/ADR had a net margin of 8.77% and a return on equity of 16.23%. View ELEKTA AB/ADR's Earnings History.
When is ELEKTA AB/ADR's next earnings date?
What is the consensus analysts' recommendation for ELEKTA AB/ADR?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ELEKTA AB/ADR in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ELEKTA AB/ADR.
Has ELEKTA AB/ADR been receiving favorable news coverage?
News coverage about EKTAY stock has been trending positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ELEKTA AB/ADR earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for ELEKTA AB/ADR.
Who are some of ELEKTA AB/ADR's key competitors?
Some companies that are related to ELEKTA AB/ADR include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Personalis (PSNL), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD) and Miragen Therapeutics (MGEN).
What other stocks do shareholders of ELEKTA AB/ADR own?
Who are ELEKTA AB/ADR's key executives?
ELEKTA AB/ADR's management team includes the folowing people:
- Mr. Laurent Leksell, Founder & Chairman (Age 67)
- Dr. Richard Hausmann, Pres & CEO (Age 59)
- Mr. Gustaf Salford, CFO & Exec. VP (Age 42)
- Mr. Steven Wort, COO & Group VP of Manufacturing & Logistics (Age 56)
- Mr. John Lapré, Chief Technology Officer (Age 55)
How do I buy shares of ELEKTA AB/ADR?
Shares of EKTAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ELEKTA AB/ADR's stock price today?
One share of EKTAY stock can currently be purchased for approximately $12.90.
How big of a company is ELEKTA AB/ADR?
ELEKTA AB/ADR has a market capitalization of $4.75 billion and generates $1.44 billion in revenue each year. The company earns $132.74 million in net income (profit) each year or $0.33 on an earnings per share basis. ELEKTA AB/ADR employs 3,800 workers across the globe.View Additional Information About ELEKTA AB/ADR.
What is ELEKTA AB/ADR's official website?
How can I contact ELEKTA AB/ADR?
ELEKTA AB/ADR's mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company can be reached via phone at 46-8-587-254-00 or via email at [email protected]
MarketBeat Community Rating for ELEKTA AB/ADR (OTCMKTS EKTAY)
MarketBeat's community ratings are surveys of what our community members think about ELEKTA AB/ADR and other stocks. Vote "Outperform" if you believe EKTAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKTAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
